Home » Epigenomics, Myriad to Hunt DNA Methylation Markers for Cancer Drug Response

Epigenomics, Myriad to Hunt DNA Methylation Markers for Cancer Drug Response

May 09, 2007
NEW YORK (GenomeWeb News) - Epigenomics today said it will collaborate with Myriad Genetics to identify DNA methylation biomarkers that may predict patient response to a cancer drug.
 
Under the collaboration, Epigenomics will use its Differential Methylation Hybridization microarray platform for genome-wide profiling of samples provided by Myriad. The company hopes to discover methylation biomarkers that are linked to sensitivity and resistance to the undisclosed marketed oncology drug.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Scan

Moving the Parts About

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

Privacy Policy Information, Please

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

This Week in Science

In Science this week: genetic overlap among many psychiatric disorders, and more.

Just Skip that Step

The Economist writes that an increasing number of scientific journals don't do peer review.

What's Popular?

In Microarrays & Multiplexing

  1. MS Risk Linked to HLA Haplotype Mediated by Altered Methylation

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.